74 enrolling by invitation. 74 Phase 2, 16 Phase 1, 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 74 | Enrolling by invitation 74 |
| Phase 1 | 16 | Enrolling by invitation 16 |
| Phase 3 | 10 | Enrolling by invitation 10 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. CD19/22 CAR-T cells - Acute Lymphobkastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Enrolling by invitation | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 17 | 2026-10-10 | 2026-10-16 |
| Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer MRG003 (Becotatug Vedotin) - Biliary Tract Neoplasms | Phase 2 | Enrolling by invitation | Jiangmen Central Hospital | 30 | 2026-09-22 | 2026-10-26 |
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma Hypofractionated Radiation Therapy - Anal Cancer | Phase 2 | Enrolling by invitation | University of Vermont Medical Center | 24 | 2026-08-26 | 2026-09-15 |
| Photobiomodulation Alone Versus Photobiomodulation Combined With Topical Oral Oxygen Therapy for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Clinical Trial sirolase xtent laser, blue m gel - Mucositis Oral, Head & Neck Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Assiut University | 46 | 2026-08-15 | 2026-10-08 |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. A single-arm, single-center clinical trial evaluating efficacy - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Enrolling by invitation | Zhejiang Provincial People's Hospital | 30 | 2026-05-01 | 2026-04-24 |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 42 | 2026-04-20 | 2026-06-01 |
| Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 55 | 2026-04-13 | 2026-10-05 |
| Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC Bronchial Arterial Chemoembolization (BACE), Systemic anti-tumor combination medications - Non-small Cell Lung Cancer(NSCLC) | Phase 2 | Enrolling by invitation | Fujian Cancer Hospital | 20 | 2026-04-09 | 2026-07-31 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction laparoscopic and endoscopic cooperative surgery - Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Enrolling by invitation | Peking University People's Hospital | 40 | 2026-04-01 | 2026-04-30 |
| HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). HVA - Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 40 | 2026-04-01 | 2026-04-08 |
| Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) - Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 50 | 2026-03-25 | 2026-10-05 |
| Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg - Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 2 | Enrolling by invitation | Hoag Memorial Hospital Presbyterian | 39 | 2026-03-05 | 2026-09-23 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors OC-EIEs - Ovarian Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Shenzhen Geno-Immune Medical Institute | 20 | 2025-12-01 | 2026-11-02 |
| Tau PET Outcomes With Anti-amyloid Immunotherapies 18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild | Phase 2 | Enrolling by invitation | Mayo Clinic | 135 | 2025-11-04 | 2026-10-30 |
Showing 20 of 74. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (4) · Glioma (4) · Head and Neck Neoplasms (4) · Cholangiocarcinoma (3) · Gallbladder Neoplasms (3) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Small Cell Lung Carcinoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Renal Cell (2)
Neoplasms by Site (45) · Neoplasms by Histologic Type (41) · Hemic and Lymphatic Diseases (20) · Digestive System Diseases (19) · Neoplasms, Glandular and Epithelial (19) · Digestive System Neoplasms (17) · Hematologic Diseases (16) · Immune System Diseases (13) · Leukemia (13) · Carcinoma (12) · Immunoproliferative Disorders (12) · Lymphoproliferative Disorders (12) · Gastrointestinal Diseases (11) · Gastrointestinal Neoplasms (10)
Carboplatin (3) · Cisplatin (3) · Radiotherapy (3) · 130-nm albumin-bound paclitaxel (2) · Azacitidine (2) · Dexamethasone (2) · Induction Chemotherapy (2) · Lenalidomide (2) · Nivolumab (2) · Opiate Substitution Treatment (2) · camrelizumab (2) · carfilzomib (2) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Alginates (1) · Bendamustine Hydrochloride (1)
Guangdong Second Provincial General Hospital (3) · First Affiliated Hospital of Zhejiang University (2) · Michael Pulsipher (2) · Peking Union Medical College Hospital (2) · Peking University (2) · SWOG Cancer Research Network (2) · Sir Run Run Shaw Hospital (2) · Sun Yat-sen University (2) · Tomsk National Research Medical Center of the Russian Academy of Sciences (2) · Yingjuan Zheng (2) · Abbisko Therapeutics Co, Ltd (1) · Akiva Mintz (1) · Assiut University (1) · Autolus Limited (1) · Beijing Bio-Targeting Therapeutics Technology Co., Ltd (1)
China (40) · United States (15) · Russia (5) · Canada (4) · France (4) · Spain (4) · Brazil (3) · Germany (3) · Poland (3) · South Korea (3) · Taiwan (3) · Israel (2) · Italy (2) · Japan (2) · United Kingdom (2)
Vladimir I Chernov, MD, Prof (2) · Adisak Wongkajornsilp, M.D., Ph.D. (1) · Anjali S Advani (1) · Carlos Becerra, MD (1) · Christopher L Anker, MD (1) · Chunyan Chen, MD, PhD (1) · Dong Lin Dong Lin, Bachelor of Medicine(BM) (1) · Guopan Yu, PhD (1) · Hye Ryun Kim (1) · Jiajie Xu (1) · Jinghui Lin Jinghui Lin, Bachelor of Medicine(BM) (1) · Lihong Weng Lihong Weng, Master of Medicine (MM) (1) · Ling Long, PhD (1)
PMID 10561263, PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 25040088, PMID 25230595, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 30280641, PMID 30285222, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 32603550, PMID 33446664, PMID 35776909, PMID 36907793, PMID 37124525, PMID 38291578, PMID 38655260, PMID 38713298, PMID 38933450, PMID 39042892, PMID 39177967, PMID 39260670, PMID 40081220, PMID 40140911, PMID 40235787, PMID 40308513
2023 (2), 2018 (1), 2025 (1)